Enovis (ENOV) Stock Analysis & AI Equity Report
Enovis (ENOV) overview
Enovis (ENOV) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 2,248m and operating profit of USD -1,124m; the year-end share price was 26.64 USD and market capitalisation was USD 1,524m. Enovis is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Enovis's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Enovis
Enovis develops, manufactures, and distributes medical devices and related services for injury prevention, reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products include orthopedic braces, therapy systems, stimulators, joint replacement implants, instrumentation, and surgical technologies. Customers include healthcare professionals, orthopedic specialists, surgeons, healthcare systems, athletes, patients, and retail consumers.
Generate the Enovis report
Enovis is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Enovis and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Enovis
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.